Full opening of four more European markets
19-10-2004
LiDCO, the UK-based, AIM-traded cardiovascular monitoring company, announces that four new European markets will soon be open to full use of its LiDCOplus cardiovascular monitor.
The UK's Medicines and Healthcare Regulatory Authority (MHRA) has notified LiDCO that the second wave Mutual Recognition Procedure for Lithium Chloride injection has been completed successfully for Denmark, Ireland, Norway and Sweden. Implementation of these EU mutual recognition approvals by each member state and full product launch in these territories is on target for the first half of 2005.
Dr Terry O'Brien, LiDCO’s CEO, stated: 'We have now successfully registered the lithium chloride injection as a pharmaceutical (in vivo diagnostic) in the majority of the major European markets. Europe is the most developed territory for the adoption of advanced minimally invasive cardiovascular monitoring. Following on from our recent product launches in Germany, Austria and Italy, we expect the growth in European sales to be further accelerated by these additional territories in the New Year.'
Notes for Editors
LiDCO is a leading developer of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. The Company’s current products are:
- the LiDCOplus and PulseCO monitors, computer-based platforms for displaying a range of real-time continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; and
- the LiDCO disposable for accurately determining cardiac output in a minimally-invasive manner.
|
